December 2010
Worldwide Biotech;Dec2010, Vol. 22 Issue 12, p1
Trade Publication
The article reports that therapeutic ultrasound technology maker EDAP TMS SA has completed its feasibility studies designed to improve cancer drug delivery with the use of ultrasound sensitive liposomes combined with High Intensity Focused Ultrasound (HIFU). According to EDAP, the research confirms that HIFU facilitates drug delivery by activating the encapsulated cancer drug called doxorubicin after solid tumors accumulation. The research was conducted in collaboration with Epitarget AS.


Related Articles

  • 1st installation in Mexico for Ablatherm.  // Medical Device Daily;2/9/2009, Vol. 13 Issue 25, p7 

    The article reports on the announcement by EDAP TMS of the first installation of its Ablatherm-high-intensity focused ultrasound (HIFU) machine at Centro Medico Puerta de Hierro Hospital in Guadalajara, Mexico under a revenue-per-procedure contract. Jorge Gutierrez Aceves, head of the Prostate...

  • Italian urologists back HIFU.  // Medical Device Daily;4/14/2009, Vol. 13 Issue 70, p7 

    The article reports that the Association of Italian Urologists (AURO) has recommended high-intensity focused ultrasound (HIFU) as a standard of care for the treatment of prostate cancer. It states the recommendation and updated guidelines are based on the number of HIFU patients treated in...

  • UK hospital newest Ablatherm-HIFU site.  // Medical Device Daily;6/26/2007, Vol. 11 Issue 122, p7 

    This article states that EDAP TMS, the Lyon, France-based developer of high-intensity focused ultrasound (HIFU) treatment of prostate cancer has introduced fixed Ablatherm-HIFU services at the Capio Springfield Hospital in Great Britain. It explains that the hospital is first site in Great...

  • EDAP's Ablatherm granted temporary reimbursement.  // Medical Device Daily;2/4/2011, Vol. 15 Issue 24, p1 

    This article reports on a special temporary reimbursement for Ablatherm-HIFU for the treatment of localized prostate cancer received by EDAP TMS, a developer of therapeutic ultrasound products, from the French National Authority for Health (HAS). The grant follows a comprehensive review of...

  • EDAP continues to expand Ablatherm-HIFU installed base.  // Medical Device Daily;12/21/2009, Vol. 13 Issue 244, p1 

    The article reports on the orders placed by La Pitie Salpetriere Hospital and Azienda Hospital for EDAP's Ablatherm-high intensity focused ultrasound (HIFU) device. The first successful Ablatherm treatments were performed in Taiwan. Chief executive officer (CEO) Marc Oczachowski says they are...

  • U.S. trial resumes for Ablatherm-HIFU.  // Medical Device Daily;5/8/2007, Vol. 11 Issue 88, p3 

    The article reports that the U.S. Phase II/III trials of EDAP TMS for its high-intensity focused ultrasound (HIFU) treatment of prostate cancer. Two additional patients at Duke University Medical Center will be subjected to the Ablatherm-HIFU treatment, a noninvasive therapy using highly-focused...

  • HIFU successful in prostate cancer treatment.  // Medical Device Daily;6/6/2012, Vol. 16 Issue 107, p3 

    The article focuses on EDAP TMS's report that its Ablatherm High Intensity Focused Ultrasound (HIFU) has successfully treated prostate cancer tumors in patients at the St-Augustin Urology Clinic in France.

  • Activation of microbubbles by low-level therapeutic ultrasound enhances the antitumor effects of doxorubicin. Yang, Shuang; Wang, Pan; Wang, Xiaobing; Su, Xiaomin; Liu, Quanhong // European Radiology;Nov2014, Vol. 24 Issue 11, p2739 

    Objective: To prove that DNA damage, intracellular reactive oxygen species (ROS) generation and loss of mitochondrial membrane potential (MMP) are contributing factors for the inhibition of cell proliferation induced by doxorubicin (DOX) administration combined with microbubble-assisted...

  • Product Briefs.  // Medical Device Daily;10/27/2010, Vol. 14 Issue 209, p5 

    This section offers news briefs concerning the medical device sector as of October 2010. CJPS Medical Systems has released VitalPoint, a medical device that can measure patients' vital signs from home. EDAP TMS has completed the first phase of the clinical protocol aimed at evaluating High...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics